We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Better, not bitter

15 May 2013 By Robert Cyran

Pharmaceutical firm Actavis has spurned interest from rivals Valeant and Mylan. Instead, the $16 billion generics manufacturer is pursuing the much smaller Warner Chilcott. That combination won’t deliver the hefty dose of cost savings that could come from a larger deal.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)